国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
International Journal of Traditional Chinese Medicine
2015年
10期
879-882
,共4页
阿尔茨海默病%清开灵注射液%中西医结合疗法%简易智能量表%日常生活活动量表
阿爾茨海默病%清開靈註射液%中西醫結閤療法%簡易智能量錶%日常生活活動量錶
아이자해묵병%청개령주사액%중서의결합요법%간역지능량표%일상생활활동량표
Alzheimer disease%Qing Kai Ling Zhu She Ye%Integrated Chinese traditional and Western medicine therapy%Mini mental state examination%Activities of daily living scale
目的 评价清开灵注射液联合盐酸多奈哌齐片治疗阿尔茨海默病(Alzheimer's disease, AD)的临床疗效.方法 将符合纳入标准的84例AD患者采用随机数字法分为2组各42例.对照组每晚口服盐酸多奈哌齐片5 mg,治疗组在此基础上加用清开灵注射液60 ml静脉滴注,共治疗20周.比较2组治疗前后简易智能量表(mini mental state examination, MMSE)、日常生活活动量表(Activity of daily living scale, ADL)评分;采用放射免疫法检测血清高敏C-反应蛋白(high-sensitivity C-reactive protein, HS-CRP)、白细胞介素-6(interleukin-6, IL-6)、丙二醛(malondialdehyde, MDA)、氧化低密度脂蛋白(oxidized low-density lipoprotein, ox-LDL)含量,评价临床疗效.结果 治疗后,治疗组血清HS-CRP[(4.18± 0.38)mg/L比(5.78±0.53)mg/L,t=15.900]、IL-6[(34.28±4.33)?g/L比(44.75±4.99)?g/L,t=10.270]、MDA[(6.04±0.98)?mol/L 比(7.43±0.69)?mol/L,t=7.516]、ox-LDL[(62.87±7.65)?g/L 比(102.56± 9.81)?g/L , t=26.677]含量均较对照组明显下降(P 均<0.01).治疗组、对照组总有效率分别为83.3%(35/42)、61.9%(26/42),2组比较差异有统计学意义(χ2=4.850,P=0.028).治疗组、对照组MMSE评分较同组治疗前升高(t值分别为8.036、7.475,P值均<0.01)、ADL评分均较同组治疗前降低(t值分别为7.818、5.960,P值均<0.01),但2组治疗后比较,差异无统计学意义(t值分别为1.633、1.710,P值分别为0.106、0.091).结论 清开灵注射液联合盐酸多奈哌齐片可有效降低AD患者血清HS-CRP、IL-6、MDA和ox-LDL含量,疗效优于单纯口服盐酸多奈哌齐片治疗.
目的 評價清開靈註射液聯閤鹽痠多奈哌齊片治療阿爾茨海默病(Alzheimer's disease, AD)的臨床療效.方法 將符閤納入標準的84例AD患者採用隨機數字法分為2組各42例.對照組每晚口服鹽痠多奈哌齊片5 mg,治療組在此基礎上加用清開靈註射液60 ml靜脈滴註,共治療20週.比較2組治療前後簡易智能量錶(mini mental state examination, MMSE)、日常生活活動量錶(Activity of daily living scale, ADL)評分;採用放射免疫法檢測血清高敏C-反應蛋白(high-sensitivity C-reactive protein, HS-CRP)、白細胞介素-6(interleukin-6, IL-6)、丙二醛(malondialdehyde, MDA)、氧化低密度脂蛋白(oxidized low-density lipoprotein, ox-LDL)含量,評價臨床療效.結果 治療後,治療組血清HS-CRP[(4.18± 0.38)mg/L比(5.78±0.53)mg/L,t=15.900]、IL-6[(34.28±4.33)?g/L比(44.75±4.99)?g/L,t=10.270]、MDA[(6.04±0.98)?mol/L 比(7.43±0.69)?mol/L,t=7.516]、ox-LDL[(62.87±7.65)?g/L 比(102.56± 9.81)?g/L , t=26.677]含量均較對照組明顯下降(P 均<0.01).治療組、對照組總有效率分彆為83.3%(35/42)、61.9%(26/42),2組比較差異有統計學意義(χ2=4.850,P=0.028).治療組、對照組MMSE評分較同組治療前升高(t值分彆為8.036、7.475,P值均<0.01)、ADL評分均較同組治療前降低(t值分彆為7.818、5.960,P值均<0.01),但2組治療後比較,差異無統計學意義(t值分彆為1.633、1.710,P值分彆為0.106、0.091).結論 清開靈註射液聯閤鹽痠多奈哌齊片可有效降低AD患者血清HS-CRP、IL-6、MDA和ox-LDL含量,療效優于單純口服鹽痠多奈哌齊片治療.
목적 평개청개령주사액연합염산다내고제편치료아이자해묵병(Alzheimer's disease, AD)적림상료효.방법 장부합납입표준적84례AD환자채용수궤수자법분위2조각42례.대조조매만구복염산다내고제편5 mg,치료조재차기출상가용청개령주사액60 ml정맥적주,공치료20주.비교2조치료전후간역지능량표(mini mental state examination, MMSE)、일상생활활동량표(Activity of daily living scale, ADL)평분;채용방사면역법검측혈청고민C-반응단백(high-sensitivity C-reactive protein, HS-CRP)、백세포개소-6(interleukin-6, IL-6)、병이철(malondialdehyde, MDA)、양화저밀도지단백(oxidized low-density lipoprotein, ox-LDL)함량,평개림상료효.결과 치료후,치료조혈청HS-CRP[(4.18± 0.38)mg/L비(5.78±0.53)mg/L,t=15.900]、IL-6[(34.28±4.33)?g/L비(44.75±4.99)?g/L,t=10.270]、MDA[(6.04±0.98)?mol/L 비(7.43±0.69)?mol/L,t=7.516]、ox-LDL[(62.87±7.65)?g/L 비(102.56± 9.81)?g/L , t=26.677]함량균교대조조명현하강(P 균<0.01).치료조、대조조총유효솔분별위83.3%(35/42)、61.9%(26/42),2조비교차이유통계학의의(χ2=4.850,P=0.028).치료조、대조조MMSE평분교동조치료전승고(t치분별위8.036、7.475,P치균<0.01)、ADL평분균교동조치료전강저(t치분별위7.818、5.960,P치균<0.01),단2조치료후비교,차이무통계학의의(t치분별위1.633、1.710,P치분별위0.106、0.091).결론 청개령주사액연합염산다내고제편가유효강저AD환자혈청HS-CRP、IL-6、MDA화ox-LDL함량,료효우우단순구복염산다내고제편치료.
Objective To observe the clinical treatment effects of Qingkailing injection on Alzheimer's disease.Methods 84 patients with AD were randomly divided into a control group and a treatment group (n=42 cases,per group). The patients in both groups orally took 5 mg of donepezil hydrochloride every night. The Qingkailing injection of 60 ml was administrated by intravenous drip in addition to oral uptake of donepezil hydrochloride to the treatment group. The total treatment period of both groups was 20 weeks. The MMSE, ADL score, HS-CRP, IL-6, MDA and ox-LDL content and the clinical treatment results and differences in the two groups before and after the treatment were observed.Results After treatment, the serum HS-CRP (4.18 ± 0.38 mg/Lvs. 5.78 ± 0.53 mg/L,t=15.900), IL-6 (34.28 ± 4.33?g/L vs.44.75 ± 4.99?g/L,t=10.270), MDA (6.04 ± 0.98?mol/L vs.7.43 ± 0.69?mol/L,t=7.516), ox-LDL (62.87 ± 7.65?g/L vs.102.56 ± 9.81?g/L, t=26.677) content of the treatment group were significantly decreased than the control group (P<0.01). The total effective rate between the treatment group and the control group had significance difference (83.3%vs. 61.9%;χ2=4.850,P=0.028). The MMSE score in both groups after the treatment were higher than those in the same group(t value were 8.036, 7.475, respectively,P<0.01), ADL scores in both groups after treatment were lower than those before treatment(t value were 7.818, 5.960, respectively,P<0.01), but no significance difference between the two groups(t value were 1.633, 1.710,respectively,P value were 0.106, 0.091, respectively).Conclusion The treatment effect of Qingkailing injection on Alzheimer's disease was sound.
